fda compounding glp-1 warning letters september 2025 Beyond the Headlines: to Compounders FDA Sends Warning Letters to

Additional risk factors include: Chronic kidney disease : Reduced renal clearance may impair B12 excretion Liver disease : Hepatic dysfunction can disrupt B12 metabolism and storage Myeloproliferative disorders : Certain blood cancers increase B12-binding proteins Concurrent medication use : Some drugs may interact with B12 metabolism, including metformin, proton pump inhibitors, and H2 antagonists Patients with these conditions should have B12 supplementation carefully monitored by their healthcare team

Several other open questions emanate from our study

Science 379 , 523524 (2023)

Articles and useful information: anticatabolics What is L-carnitine and what is it for

9 AdamsTDDavidsonLELitwinSEKolotkinRLLaMonteMJPendletonRCet al